What's in Kala Pharmaceuticals, Inc.'s pipeline?

Kala Pharmaceuticals, Inc. has 8 drugs in our index: 0 marketed, 0 filed, 6 in Phase 3, 1 in Phase 2, 1 in Phase 1.

Which companies overlap with Kala Pharmaceuticals, Inc.'s portfolio?

Top competitors by shared drug class: Pfizer, Bausch & Lomb Incorporated, Federal University of São Paulo, LEO Pharma, Sun Pharmaceutical Industries, Inc..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/kala-pharmaceuticals-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Kala Pharmaceuticals, Inc. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Kala Pharmaceuticals, Inc. pipeline: 0 marketed, 0 filed, 6 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 6 Phase 3 1 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
KPI-121 0.25%	KPI-121 0.25%	phase 3	Topical ophthalmic anti-inflammatory/lubricant		Ophthalmology
Vehicle of KPI-121 0.25%	Vehicle of KPI-121 0.25%	phase 3	corticosteroid		Ophthalmology
KPI-121 Ophthalmic Suspension	KPI-121 Ophthalmic Suspension	phase 3	TRPV1 antagonist / Topical anti-inflammatory	TRPV1 (Transient Receptor Potential Vanilloid 1)	Ophthalmology
KPI-121 1.0%	KPI-121 1.0%	phase 3	Topical corticosteroid	Glucocorticoid receptor	Ophthalmology
KPI-121 0.25% Ophthalmic Suspension	KPI-121 0.25% Ophthalmic Suspension	phase 3	Ophthalmic anti-inflammatory suspension		Ophthalmology
Vehicle of KPI-121 1.0%	Vehicle of KPI-121 1.0%	phase 3	corticosteroid		Ophthalmology

Therapeutic area mix

Ophthalmology · 6

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Pfizer · 2 shared drug classes
Bausch & Lomb Incorporated · 2 shared drug classes
Federal University of São Paulo · 2 shared drug classes
LEO Pharma · 2 shared drug classes
Sun Pharmaceutical Industries, Inc. · 2 shared drug classes
Astellas Pharma Inc · 1 shared drug class
Apotex Inc. · 1 shared drug class
Al-Azhar University · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Kala Pharmaceuticals, Inc.:

Cite this brief

Drug Landscape (2026). Kala Pharmaceuticals, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/kala-pharmaceuticals-inc. Accessed 2026-05-16.